focus -WSS

focus

author：fashion 2025-10-01 04:33:12 - browse：6241

The Food and Drug Administration on Friday approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease that delivers a potential cure for people born with the chronic and life-shortening blood disorder.

The new medicine, called Casgevy, is made by Vertex Pharmaceuticals and CRISPR Therapeutics. Its authorization is a scientific triumph for the technology that can efficiently and precisely repair DNA mutations — ushering in a new era of genetic medicines for inherited diseases.

In a clinical trial, Casgevy was shown to eliminate recurrent episodes of debilitating pain caused by sickle cell, which afflicts approximately 100,000 people in the U.S., a vast majority of whom are Black. The therapy, whose scientific name is exa-cel, is described as a potential cure because the genetic fix enabled by CRISPR is designed to last a lifetime, although confirmation will require years of follow-up.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： CDC director unscathed in first congressional testimony

entertainment

WSS

As biotech industry slumps, bioscience job market is upside down

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Will the market for weight loss drugs really reach $100 billion?

Diagnostic tests are hitting their mathematical limits

CDC director unscathed in first congressional testimony

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

focus

focus

knowledge

Activists slam private health insurers over coverage restrictions

The surgeon had a dilemma only a Nazi medical text could resolve

As demand for Covid shots wanes, Moderna seeks its next success

EU regulator recommends expanding Mounjaro approval to obesity

Supreme Court strikes down use of affirmative action

Research misconduct: Proposed new rules face resistance

After affirmative action ruling, medical educators look to 'holistic review'

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Merck, J&J, and long Covid

leisure time

Mayo Clinic plans $5B tech

What don’t we know about an Alzheimer’s drug side effect?

Pediatric cancer treatments threatened by a new FDA policy

CDC director unscathed in first congressional testimony

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

UnitedHealth’s Optum accused of antitrust violations in California

leisure time

hotspot

entertainment

entertainment